Target proteins of C/EBPalphap30 in AML: C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9
- PMID: 17671234
- DOI: 10.1182/blood-2007-01-071035
Target proteins of C/EBPalphap30 in AML: C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9
Abstract
CCAAT/enhancer-binding protein alpha (C/EBPalpha) is a critical regulator for early myeloid differentiation. Mutations in C/EBPalpha occur in 10% of patients with acute myeloid leukemia (AML), leading to the expression of a 30-kDa dominant-negative isoform (C/EBPalphap30). In the present study, using a global proteomics approach to identify the target proteins of C/EBPalphap30, we show that Ubc9, an E2-conjugating enzyme essential for sumoylation, is increased in its expression when C/EBPalphap30 is induced. We confirmed the increased expression of Ubc9 in patients with AML with C/EBPalphap30 mutations compared with other subtypes. We further confirmed that the increase of Ubc9 expression was mediated through increased transcription. Furthermore, we show that Ubc9-mediated enhanced sumoylation of C/EBPalphap42 decreases the transactivation capacity on a minimal C/EBPalpha promoter. Importantly, overexpression of C/EBPalphap30 in granulocyte colony-stimulating factor (G-CSF)-stimulated human CD34(+) cells leads to a differentiation block, which was overcome by the siRNA-mediated silencing of Ubc9. In summary, our data indicate that Ubc9 is an important C/EBPalphap30 target through which C/EBPalphap30 enhances the sumoylation of C/EBPalphap42 to inhibit granulocytic differentiation.
Similar articles
-
Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia.J Biol Chem. 2012 Sep 21;287(39):32728-37. doi: 10.1074/jbc.M112.373274. Epub 2012 Jul 31. J Biol Chem. 2012. PMID: 22851180 Free PMC article.
-
C/EBPα in normal and malignant myelopoiesis.Int J Hematol. 2015 Apr;101(4):330-41. doi: 10.1007/s12185-015-1764-6. Epub 2015 Mar 10. Int J Hematol. 2015. PMID: 25753223 Free PMC article. Review.
-
C/EBPalphap30 plays transcriptional regulatory roles distinct from C/EBPalphap42.Cell Res. 2007 Apr;17(4):374-83. doi: 10.1038/sj.cr.7310121. Cell Res. 2007. PMID: 17242690
-
C/EBPalphap30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding.Oncogene. 2004 Jan 22;23(3):716-25. doi: 10.1038/sj.onc.1207172. Oncogene. 2004. PMID: 14737106
-
SUMO Ubc9 enzyme as a viral target.IUBMB Life. 2014 Jan;66(1):27-33. doi: 10.1002/iub.1240. Epub 2014 Jan 6. IUBMB Life. 2014. PMID: 24395713 Review.
Cited by
-
E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBPα for ubiquitin-mediated proteasome degradation.Cell Death Dis. 2013 Apr 18;4(4):e590. doi: 10.1038/cddis.2013.120. Cell Death Dis. 2013. PMID: 23598402 Free PMC article.
-
The SUMO Pathway in Hematomalignancies and Their Response to Therapies.Int J Mol Sci. 2019 Aug 9;20(16):3895. doi: 10.3390/ijms20163895. Int J Mol Sci. 2019. PMID: 31405039 Free PMC article. Review.
-
Functional roles of C/EBPα and SUMO‑modification in lung development.Int J Mol Med. 2017 Oct;40(4):1037-1046. doi: 10.3892/ijmm.2017.3111. Epub 2017 Aug 29. Int J Mol Med. 2017. PMID: 28902364 Free PMC article.
-
TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently.Blood Adv. 2023 Jul 11;7(13):3155-3168. doi: 10.1182/bloodadvances.2022007956. Blood Adv. 2023. PMID: 36809797 Free PMC article.
-
Dysregulation of the C/EBPalpha differentiation pathway in human cancer.J Clin Oncol. 2009 Feb 1;27(4):619-28. doi: 10.1200/JCO.2008.17.9812. Epub 2008 Dec 15. J Clin Oncol. 2009. PMID: 19075268 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous